

Supplementary Material

Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study

Michael Sticherling^a, Tess McPherson^b, Raúl de Lucas Laguna^c, Antonio Costanzo^{d,e}, Catherine Reed^{f*}, Esther Artime^g, Camille Robert^h, James Lucasⁱ, Christopher Schuster^j, Emmanuel Mahé^k

^aDepartment of Dermatology, Psoriasis-Center, Deutsches Zentrum Immuntherapie (DZI), University of Erlangen, Erlangen, Germany; ^bChurchill Hospital, Oxford, UK; ^cServicio de Dermatología Infantil, Hospital Universitario La Paz, Madrid, Spain; ^dDermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ^eDermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ^fEli Lilly and Company, Bracknell, UK; ^gEli Lilly and Company, Madrid, Spain; ^hLilly France SAS, Neuilly Sur Seine, France; ⁱAdelphi Real-World, Macclesfield, UK; ^jEli Lilly Regional Operations GmbH, Vienna, Austria; ^kService de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France

*Corresponding Author: Catherine Reed

Email: reed_catherine@lilly.com

Supplementary Table 1 Number of patient report forms completed, by country.

Country	Overall	Weighing 25–50 kg	Weighing >50 kg
Overall	1919	772 (40.2%)	1147 (59.8%)
France	414	196 (47.3%)	218 (52.7%)
Germany	462	170 (36.8%)	292 (63.2%)
Italy	389	184 (47.3%)	205 (52.7%)
Spain	429	156 (36.4%)	273 (63.6%)
UK	225	66 (29.3%)	159 (70.7%)

Supplementary Table 2 Patient characteristics and history of psoriasis at the time of data collection, by country and weight category.

Parameter ^a	France			Germany			Italy			Spain			UK		
	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg
Number and percentage of patients	414	196 (47.3%)	218 (52.7%)	462	170 (36.8%)	292 (63.2%)	389	184 (47.3%)	205 (52.7%)	429	156 (36.4%)	273 (63.6%)	225	66 (29.3%)	159 (70.7%)
Current age (years)															
Mean ± SD	14.1 ± 2.9	12.3 ± 3.0	15.6 ± 1.7	13.7 ± 2.9	10.9 ± 2.5	15.4 ± 1.5	13.2 ± 3.1	11.0 ± 2.8	15.1 ± 1.7	14.2 ± 2.9	11.6 ± 2.8	15.6 ± 1.6	14.4 ± 2.6	11.5 ± 2.5	15.6 ± 1.4
Median [IQR]	15.0 [12.0, 16.0]	13.0 [10.0, 15.0]	16.0 [15.0, 17.0]	15.0 [12.0, 16.0]	11.0 [9.0, 12.0]	16.0 [14.0, 16.0]	14.0 [11.0, 16.0]	11.0 [9.0, 13.0]	16.0 [14.0, 16.0]	15.0 [12.0, 16.0]	12.0 [10.0, 14.0]	16.0 [15.0, 17.0]	15.0 [13.0, 16.0]	11.0 [9.0, 13.0]	16.0 [15.0, 17.0]
Male	230 (55.6%)	78 (39.8%)	152 (69.7%)	266 (57.6%)	83 (48.8%)	183 (62.7%)	229 (58.9%)	86 (46.7%)	143 (69.8%)	240 (55.9%)	70 (44.9%)	170 (62.3%)	126 (56.0%)	35 (53.0%)	91 (57.2%)
Current body mass index															
Mean ± SD	21.1 ± 6.0	19.6 ± 5.4	22.5 ± 6.2	21.1 ± 2.7	19.1 ± 2.3	22.3 ± 2.3	21.4 ± 9.3	19.7 ± 3.1	22.9 ± 12.2	23.0 ± 10.9	21.0 ± 12.5	24.2 ± 9.8	23.8 ± 10.6	20.2 ± 6.9	25.3 ± 11.5
Median [IQR]	20.3 [19.0, 22.0]	18.7 [18.0, 20.0]	22.0 [20.0, 24.0]	21.0 [19.0, 23.0]	18.8 [18.0, 20.0]	22.0 [21.0, 23.0]	20.8 [19.0, 23.0]	19.2 [18.0, 21.0]	22.6 [21.0, 24.0]	21.6 [20.0, 24.0]	19.3 [18.0, 21.0]	22.7 [21.0, 25.0]	22.1 [20.0, 24.0]	19.2 [18.0, 20.0]	23.4 [21.0, 27.0]
Type of psoriasis															
Plaque	371 (89.6%)	177 (90.3%)	194 (89.0%)	445 (96.3%)	165 (97.1%)	280 (95.9%)	326 (83.8%)	153 (83.2%)	173 (84.4%)	386 (90.0%)	140 (89.7%)	246 (90.1%)	206 (91.6%)	59 (89.4%)	147 (92.5%)
Other	43 (10.4%)	19 (9.7%)	24 (11.0%)	17 (3.7%)	5 (2.9%)	12 (4.1%)	63 (16.2%)	31 (16.8%)	32 (15.6%)	43 (10.0%)	16 (10.3%)	27 (9.9%)	19 (8.4%)	7 (10.6%)	12 (7.5%)
Age at diagnosis (years)															
Mean ± SD	10.8 ± 3.6	9.7 ± 3.2	11.8 ± 3.6	11.9 ± 3.1	9.7 ± 2.3	13.5 ± 2.6	11.0 ± 3.1	9.3 ± 2.7	12.7 ± 2.6	11.5 ± 3.9	9.1 ± 3.3	12.9 ± 3.6	12.1 ± 3.1	9.0 ± 2.4	13.3 ± 2.5
Median [IQR]	11.0 [8.0, 14.0]	10.0 [8.0, 12.0]	13.0 [10.0, 14.0]	12.0 [10.0, 15.0]	10.0 [8.0, 11.0]	14.0 [12.0, 15.0]	11.0 [9.0, 13.0]	9.0 [7.0, 11.0]	13.0 [11.0, 15.0]	12.0 [9.0, 15.0]	9.0 [7.0, 11.0]	14.0 [11.0, 16.0]	13.0 [9.0, 15.0]	9.0 [7.0, 11.0]	14.0 [12.0, 15.0]
Time since diagnosis (years)															
Mean ± SD	3.5 ± 3.2	2.9 ± 2.8	4.1 ± 3.5	1.9 ± 2.2	1.3 ± 1.5	2.3 ± 2.4	2.3 ± 2.2	1.9 ± 2.1	2.7 ± 2.3	3.0 ± 3.0	2.7 ± 2.7	3.1 ± 3.2	2.5 ± 2.1	2.5 ± 1.8	2.6 ± 2.3
Median [IQR]	2.5 [1.1, 5.1]	2.2 [0.5, 4.8]	3.1 [1.5, 5.7]	1.1 [0.5, 2.6]	0.8 [0.4, 1.7]	1.4 [0.5, 3.2]	1.6 [0.6, 3.1]	1.3 [0.5, 2.6]	2.1 [1.1, 4.1]	2.0 [1.0, 4.0]	2.1 [1.0, 3.9]	2.0 [1.1, 4.1]	1.9 [1.1, 3.4]	2.2 [1.1, 3.3]	1.9 [1.1, 3.8]
Severity of psoriasis at diagnosis															

Mild	87 (21.0%)	46 (23.5%)	41 (18.8%)	220 (47.6%)	76 (44.7%)	144 (49.3%)	113 (29.0%)	66 (35.9%)	47 (22.9%)	157 (36.6%)	76 (48.7%)	81 (29.7%)	64 (28.4%)	31 (47.0%)	33 (20.8%)
Moderate/Severe	327 (79.0%)	150 (76.5%)	177 (81.2%)	242 (52.4%)	94 (55.3%)	148 (50.7%)	276 (71.0%)	118 (64.1%)	158 (77.1%)	272 (63.4%)	80 (51.3%)	192 (70.3%)	161 (71.6%)	35 (53.0%)	126 (79.2%)
BSA affected at diagnosis (%)															
Mean ± SD	21.0 ± 19.6	20.7 ± 21.0	21.4 ± 18.3	12.6 ± 10.3	12.5 ± 11.0	12.7 ± 9.7	21.0 ± 17.1	19.8 ± 17.3	22.2 ± 16.9	10.0 ± 9.0	8.7 ± 8.8	10.8 ± 9.0	12.0 ± 13.0	9.6 ± 10.5	13.1 ± 13.9
Median [IQR]	15.0 [8.0, 25.0]	14.0 [8.0, 22.0]	15.0 [10.0, 25.0]	10.0 [8.0, 15.0]	10.0 [6.0, 15.0]	10.0 [8.0, 15.0]	15.0 [8.0, 30.0]	12.5 [8.0, 26.0]	18.5 [8.0, 35.0]	8.0 [5.0, 12.0]	7.5 [4.0, 10.0]	8.0 [5.0, 15.0]	9.0 [5.0, 15.0]	5.0 [2.0, 15.0]	10.0 [5.0, 15.0]
Family history of psoriasis	210 (50.7%)	95 (48.5%)	115 (52.8%)	154 (33.3%)	60 (35.3%)	94 (32.2%)	201 (51.7%)	85 (46.2%)	116 (56.6%)	234 (54.5%)	83 (53.2%)	151 (55.3%)	100 (44.4%)	30 (45.5%)	70 (44.0%)
Diagnosis of psoriatic arthritis	19 (4.6%)	7 (3.6%)	12 (5.5%)	20 (4.3%)	5 (2.9%)	15 (5.1%)	16 (4.1%)	4 (2.2%)	12 (5.9%)	17 (4.0%)	9 (5.8%)	8 (2.9%)	10 (4.4%)	3 (4.5%)	7 (4.4%)

Values are shown as mean ± standard deviation or n (%) unless otherwise indicated.

^aNumber of patients was lower for some parameters.

BSA, body surface area; IQR, interquartile range; SD, standard deviation.

Supplementary Table 3 Current treatment characteristics, by type of prescriber and country

Treatment	Overall (N=1919)			France (N=414)			Germany (N=462)			Italy (N=389)			Spain (N=429)			UK (N=225)		
	Dermatologist	Pediatrician	PCP	Dermatologist	Pediatrician	PCP	Dermatologist	Pediatrician	PCP	Dermatologist	Pediatrician	PCP	Dermatologist	Pediatrician	PCP	Dermatologist	Pediatrician	PCP
Type of prescriber																		
Number and percentage of prescribers	1150 (59.9%)	329 (17.1%)	440 (22.9%)	208 (50.2%)	85 (20.5%)	121 (29.2%)	270 (58.4%)	103 (22.3%)	89 (19.3%)	236 (60.7%)	99 (25.4%)	54 (13.9%)	302 (70.4%)	42 (9.8%)	85 (19.8%)	134 (59.6%)	0	91 (40.4%)
Severity of psoriasis immediately prior to current/most recent treatment regimen																		
Mild																		
Moderate/Severe	232 (20.2%) 918 (79.8%)	122 (37.1%) 207 (62.9%)	187 (42.5%) 253 (57.5%)	19 (9.1%) 189 (90.9%)	12 (14.1%) 73 (85.9%)	28 (23.1%) 93 (76.9%)	83 (30.7%) 187 (69.3%)	45 (43.7%) 58 (56.3%)	52 (58.4%) 37 (41.6%)	37 (15.7%) 199 (84.3%)	44 (44.4%) 55 (55.6%)	19 (35.2%) 35 (64.8%)	72 (23.8%) 230 (76.2%)	21 (50.0%) 21 (50.0%)	44 (51.8%) 41 (48.2%)	21 (15.7%) 113 (84.3%)	–	44 (48.4%) 47 (51.6%)
Current severity of psoriasis																		
Mild	933 (81.1%)	254 (77.2%)	349 (79.3%)	159 (76.4%)	50 (58.8%)	78 (64.5%)	217 (80.4%)	90 (84.4%)	80 (89.9%)	196 (83.1%)	80 (80.8%)	40 (74.1%)	246 (81.5%)	34 (81.0%)	76 (89.4%)	115 (85.8%)	–	75 (82.4%)
Moderate/Severe	217 (18.9%)	75 (22.8%)	91 (20.7%)	49 (23.6%)	35 (41.2%)	43 (35.5%)	53 (19.6%)	13 (12.6%)	9 (10.1%)	40 (16.9%)	19 (19.2%)	14 (25.9%)	56 (18.5%)	8 (19.0%)	9 (10.6%)	19 (14.2%)	–	16 (17.6%)
Topical only																		
Topical corticosteroid	499 (43.4%) 301 (26.2%)	248 (75.4%) 117 (35.6%)	386 (87.7%) 230 (52.3%)	74 (35.6%) 68 (32.7%)	61 (71.8%) 20 (23.5%)	104 (86.0%) 80 (66.1%)	151 (55.9%) 68 (25.2%)	79 (76.7%) 38 (36.9%)	74 (83.1%) 37 (41.6%)	85 (36.0%) 49 (20.8%)	83 (83.8%) 31 (31.3%)	41 (75.9%) 24 (44.4%)	140 (46.4%) 90 (29.8%)	25 (59.5%) 28 (66.7%)	82 (96.5%) 43 (50.6%)	49 (36.6%) 26 (19.4%)	–	85 (93.4%) 46 (50.5%)
Topical non-corticosteroid	258 (22.4%)	156 (47.4%)	155 (35.2%)	39 (18.8%)	31 (36.5%)	24 (19.8%)	117 (43.3%)	53 (51.5%)	49 (55.1%)	48 (20.3%)	68 (68.7%)	20 (37.0%)	29 (9.6%)	4 (9.5%)	18 (21.2%)	25 (18.7%)	–	44 (48.4%)
Topical combination product	311 (27.0%)	86 (26.1%)	101 (23.0%)	30 (14.4%)	45 (52.9%)	19 (15.7%)	80 (29.6%)	10 (9.7%)	14 (15.7%)	45 (19.1%)	17 (17.2%)	19 (35.2%)	105 (34.8%)	14 (33.3%)	26 (30.6%)	51 (38.1%)	–	23 (25.3%)
Phototherapy (PUVA, UVB)	77 (6.7%)	37 (11.2%)	25 (5.7%)	15 (7.2%)	8 (9.4%)	5 (4.1%)	21 (7.8%)	9 (8.7%)	10 (11.2%)	16 (6.8%)	5 (5.1%)	8 (14.8%)	17 (5.6%)	15 (35.7%)	1 (1.2%)	8 (6.0%)	–	1 (1.1%)
Conventional systemics																		
Methotrexate	167 (14.5%) 96 (8.5%)	23 (7.0%) 22 (6.7%)	18 (4.1%) 12 (2.7%)	33 (15.9%) 20 (9.9%)	4 (4.7%) 3 (3.6%)	5 (4.1%) 3 (2.5%)	21 (7.8%) 20 (7.4%)	7 (6.8%) 7 (6.8%)	6 (6.7%) 3 (3.4%)	35 (14.8%) 8 (3.5%)	4 (4.0%) 4 (4.0%)	3 (5.6%) 3 (5.6%)	38 (12.6%) 23 (7.6%)	8 (19.0%) 8 (19.0%)	1 (1.2%) 1 (1.2%)	40 (29.9%) 25 (18.8%)	–	3 (3.3%) 2 (2.2%)
Cyclosporine	46 (4.1%)	1 (0.3%)	3 (0.7%)	2 (1.0%)	0	1 (0.8%)	0	0	1 (1.1%)	27 (11.9%)	0	0	10 (3.3%)	1 (2.4%)	0	7 (5.3%)	–	1 (1.1%)
Acitretin	23 (2.0%)	1 (0.3%)	1 (0.2%)	11 (5.4%)	1 (1.2%)	1 (0.8%)	0	0	0	0	0	0	5 (1.7%)	0	0	7 (5.3%)	–	0
Fumarate	3 (0.3%)	0	2 (0.5%)	0	0	0	1 (0.4%)	0	2 (2.2%)	0	0	0	1 (0.3%)	0	0	1 (0.8%)	–	0
Biologics																		
Etanercept	407 (35.4%)	44 (13.4%)	15 (3.4%)	90 (43.3%)	16 (18.8%)	8 (6.6%)	82 (30.4%)	9 (8.7%)	1 (1.1%)	90 (38.1%)	9 (9.1%)	3 (5.6%)	107 (35.4%)	10 (23.8%)	1 (1.2%)	38 (28.4%)	–	2 (2.2%)
Etanercept or biosimilar	67 (5.9%)	9 (2.7%)	4 (0.9%)	18 (8.9%)	5 (6.0%)	2 (1.7%)	11 (4.1%)	0	0	15 (6.6%)	2 (2.0%)	1 (1.9%)	21 (7.0%)	2 (4.8%)	1 (1.2%)	2 (1.5%)	–	0
Adalimumab	84 (7.3%)	15 (4.6%)	8 (1.8%)	20 (9.6%)	7 (8.2%)	5 (4.1%)	14 (5.2%)	2 (1.9%)	0	23 (9.7%)	2 (2.0%)	2 (3.7%)	24 (7.9%)	4 (9.5%)	1 (1.2%)	3 (2.2%)	–	0
Adalimumab or biosimilar	190 (16.8%)	25 (7.6%)	6 (1.4%)	50 (24.8%)	6 (7.1%)	3 (2.5%)	40 (14.9%)	6 (5.8%)	1 (1.1%)	40 (17.7%)	7 (7.1%)	1 (1.9%)	41 (13.6%)	6 (14.3%)	0	19 (14.3%)	–	1 (1.1%)

	232 (20.2%) 91 (8.0%)	26 (7.9%) 3 (0.9%)	6 (1.4%) 1 (0.2%)	53 (25.5%) 17 (8.4%)	6 (7.1%) 3 (3.6%)	3 (2.5%) 0	50 (18.5%) 18 (6.7%)	7 (6.8%) 0	1 (1.1%) 0	59 (25.0%) 8 (3.5%)	7 (7.1%) 0	1 (1.9%) 0	44 (14.6%) 39 (13.0%)	6 (14.3%) 0	0 0	26 (19.4%) 9 (6.8%)	— —	1 (1.1%) 1 (1.1%)
Ever received a biologic	435 (37.8%)	49 (14.9%)	17 (3.9%)	99 (47.6%)	21 (24.7%)	10 (8.3%)	85 (31.5%)	9 (8.7%)	1 (1.1%)	97 (41.1%)	9 (9.1%)	3 (5.6%)	115 (38.1%)	10 (23.8%)	1 (1.2%)	39 (29.1%)	—	2 (2.2%)

Values are shown as n (%).

PUVA, psoralen and ultraviolet A; UVB, ultraviolet B.

Supplementary Table 4 Current treatment characteristics, by country and weight category.

Treatment ^a	France			Germany			Italy			Spain			UK		
	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg	Overall	25–50 kg	>50 kg
Number and percentage of patients	414	196 (47.3%)	218 (52.7%)	462	170 (36.8%)	292 (63.2%)	389	184 (47.3%)	205 (52.7%)	429	156 (36.4%)	273 (63.6%)	225	66 (29.3%)	159 (70.7%)
Severity of psoriasis immediately prior to current/most recent treatment regimen															
Mild	59 (14.3%)	35 (17.9%)	24 (11.0%)	180 (39.0%)	69 (40.6%)	111 (38.0%)	100 (25.7%)	60 (32.6%)	40 (19.5%)	137 (31.9%)	68 (43.6%)	69 (25.3%)	65 (28.9%)	29 (43.9%)	36 (22.6%)
Moderate/Severe	355 (85.7%)	161 (82.1%)	194 (89.0%)	282 (61.0%)	101 (59.4%)	181 (62.0%)	289 (74.3%)	124 (67.4%)	165 (80.5%)	292 (68.1%)	88 (56.4%)	204 (74.7%)	160 (71.1%)	37 (56.1%)	123 (77.4%)
Current severity of psoriasis															
Mild	287 (69.3%)	130 (66.3%)	157 (72.0%)	387 (83.8%)	142 (83.5%)	245 (83.9%)	316 (81.2%)	155 (84.2%)	161 (78.5%)	356 (83.0%)	135 (86.5%)	221 (81.0%)	190 (84.4%)	56 (84.8%)	134 (84.3%)
Moderate/Severe	127 (30.7%)	66 (33.7%)	61 (28.0%)	75 (16.2%)	28 (16.5%)	47 (16.1%)	73 (18.8%)	29 (15.8%)	44 (21.5%)	73 (17.0%)	21 (13.5%)	52 (19.0%)	35 (15.6%)	10 (15.2%)	25 (15.7%)
Topical only	239 (57.7%)	128 (65.3%)	111 (50.9%)	304 (65.8%)	135 (79.4%)	169 (57.9%)	209 (53.7%)	127 (69.0%)	82 (40.0%)	247 (57.6%)	104 (66.7%)	143 (52.4%)	134 (59.6%)	49 (74.2%)	85 (53.5%)
Topical corticosteroid ^b	168 (41.4%)	90 (46.4%)	78 (36.8%)	143 (31.0%)	55 (32.4%)	88 (30.2%)	104 (27.4%)	62 (34.6%)	42 (21.0%)	161 (37.6%)	68 (43.6%)	93 (34.2%)	72 (32.1%)	25 (37.9%)	47 (29.7%)
Topical non-corticosteroid ^b	94 (23.2%)	45 (23.2%)	49 (23.1%)	219 (47.5%)	108 (63.5%)	111 (38.1%)	136 (35.9%)	71 (39.7%)	65 (32.5%)	51 (11.9%)	17 (10.9%)	34 (12.5%)	69 (30.8%)	25 (37.9%)	44 (27.8%)
Topical combination product ^b	94 (23.2%)	47 (24.2%)	47 (22.2%)	104 (22.6%)	28 (16.5%)	76 (26.1%)	81 (21.4%)	38 (21.2%)	43 (21.5%)	145 (33.9%)	57 (36.5%)	88 (32.4%)	74 (33.0%)	24 (36.4%)	50 (31.6%)
Phototherapy (PUVA, UVB)^b	28 (6.9%)	16 (8.2%)	12 (5.7%)	40 (8.7%)	14 (8.2%)	26 (8.9%)	29 (7.7%)	12 (6.7%)	17 (8.5%)	33 (7.7%)	13 (8.3%)	20 (7.4%)	9 (4.0%)	2 (3.0%)	7 (4.4%)
Conventional systemics	32 (7.7%)	12 (6.1%)	20 (9.2%)	32 (6.9%)	9 (5.3%)	23 (7.9%)	40 (10.3%)	15 (8.2%)	25 (12.2%)	39 (9.1%)	15 (9.6%)	24 (8.8%)	43 (19.1%)	5 (7.6%)	38 (23.9%)
Methotrexate ^b	26 (6.4%)	9 (4.6%)	17 (8.0%)	30 (6.5%)	7 (4.1%)	23 (7.9%)	15 (4.0%)	7 (3.9%)	8 (4.0%)	32 (7.5%)	16 (10.3%)	16 (5.9%)	27 (12.1%)	4 (6.1%)	23 (14.6%)

Cyclosporine ^b	3 (0.7%)	0	3 (1.4%)	1 (0.2%)	1 (0.6%)	0	27 (7.1%)	8 (4.5%)	19 (9.5%)	11 (2.6%)	6 (3.8%)	5 (1.8%)	8 (3.6%)	0	8 (5.1%)
Acitretin ^b	13 (3.2%)	5 (2.6%)	8 (3.8%)	0	0	0	0	0	0	5 (1.2%)	0	5 (1.8%)	7 (3.1%)	1 (1.5%)	6 (3.8%)
Fumarate ^b	0	0	0	3 (0.7%)	1 (0.6%)	2 (0.7%)	0	0	0	1 (0.2%)	0	1 (0.4%)	1 (0.4%)	0	1 (0.6%)
Biologics	114 (27.5%)	41 (20.9%)	73 (33.5%)	92 (19.9%)	14 (8.2%)	78 (26.7%)	102 (26.2%)	26 (14.1%)	76 (37.1%)	118 (27.5%)	30 (19.2%)	88 (32.2%)	40 (17.8%)	10 (15.2%)	30 (18.9%)
Etanercept ^b	25 (6.2%)	11 (5.7%)	14 (6.6%)	11 (2.4%)	1 (0.6%)	10 (3.4%)	18 (4.7%)	3 (1.7%)	15 (7.5%)	24 (5.6%)	10 (6.4%)	14 (5.1%)	2 (0.9%)	2 (3.0%)	0
Etanercept or biosimilar ^b	32 (7.9%)	16 (8.2%)	16 (7.5%)	16 (3.5%)	1 (0.6%)	15 (5.2%)	27 (7.1%)	7 (3.9%)	20 (10.0%)	29 (6.8%)	12 (7.7%)	17 (6.3%)	3 (1.3%)	2 (3.0%)	1 (0.6%)
Adalimumab ^b	59 (14.5%)	16 (8.2%)	43 (20.3%)	47 (10.2%)	8 (4.7%)	39 (13.4%)	48 (12.7%)	16 (8.9%)	32 (16.0%)	47 (11.0%)	12 (7.7%)	35 (12.9%)	20 (8.9%)	8 (12.1%)	12 (7.6%)
Adalimumab or biosimilar ^b	62 (15.3%)	17 (8.8%)	45 (21.2%)	58 (12.6%)	11 (6.5%)	47 (16.2%)	67 (17.7%)	18 (10.1%)	49 (24.5%)	50 (11.7%)	12 (7.7%)	38 (14.0%)	27 (12.1%)	8 (12.1%)	0
Ustekinumab ^b	20 (4.9%)	8 (4.1%)	12 (5.7%)	18 (3.9%)	2 (1.2%)	16 (5.5%)	8 (2.1%)	1 (0.6%)	7 (3.5%)	39 (9.1%)	6 (3.8%)	33 (12.1%)	10 (4.5%)	0	10 (6.3%)
Ever received a biologic	130 (31.4%)	47 (24.0%)	83 (38.1%)	95 (20.6%)	14 (8.2%)	81 (27.7%)	109 (28.0%)	30 (16.3%)	79 (38.5%)	126 (29.4%)	34 (21.8%)	92 (33.7%)	41 (18.2%)	10 (15.2%)	31 (19.5%)

Values are shown as n (%).

^aNumber of patients was lower for some parameters.

^bPercentages based on the number of patients with a treatment history: number of patients with a treatment history overall, for patients weighing 25–50 kg and for patients weighing >50 kg = 406, 194, 212 for France; 461, 170, 291 for Germany; 379, 179, 200 for Italy; 428, 156, 272 for Spain; and 224, 66, 158 for the UK.

PUVA, psoralen and ultraviolet A; UVB, ultraviolet B.

Supplementary Table 5 Length of time in weeks on biologic treatment for patients currently taking biologics, overall and by weight category for each country.


Country	Overall	Weighing 25–50 kg	Weighing >50 kg
France			
n	112	40	72
Mean ± SD	34.3 ± 28.2	27.0 ± 21.8	38.3 ± 30.6
Median [IQR]	24.0 [16.0, 48.0]	18.0 [12.0, 41.0]	30.0 [16.0, 52.0]
Germany			
n	91	14	77
Mean ± SD	26.1 ± 22.3	28.2 ± 19.0	25.7 ± 23.0
Median [IQR]	20.0 [10.0, 36.0]	21.5 [14.0, 47.0]	20.0 [10.0, 36.0]
Italy			
n	102	26	76
Mean ± SD	35.7 ± 29.3	39.2 ± 27.2	34.6 ± 39.9
Median [IQR]	24.0 [12.0, 50.0]	35.0 [12.0, 52.0]	24.0 [12.0, 48.0]
Spain			
n	118	30	88
Mean ± SD	32.7 ± 29.8	40.0 ± 34.2	30.2 ± 19.8
Median [IQR]	24.0 [12.0, 50.0]	31.0 [12.0, 52.0]	24.0 [12.0, 48.0]
UK			
n	40	10	30
Mean ± SD	37.4 ± 16.9	36.1 ± 17.3	37.9 ± 17.1
Median [IQR]	35.5 [24.0, 52.0]	35.0 [22.0, 52.0]	35.5 [24.0, 52.0]

IQR, interquartile range; SD, standard deviation.

Supplementary Fig. 1

Number and percentage of physicians participating in

the survey, by country. PCP, primary care physician.




Supplementary Fig. 2


Treatments received according to disease severity prior

to the initiation of current treatment, by weight category for (a) France, (b) Germany, (c) Italy, (d) Spain, and (e) the UK.


(a) France




(b) Germany




(c) Italy



(d) Spain




(e) UK




Supplementary Fig. 3

Age of patients at biologic initiation, presented as the percentage of patients in each year group, overall and by country. Percentages are slightly under or over 100% due to rounding.




Supplementary Fig. 4 Current (a) weight and (b) body mass index (BMI) of patients receiving biologics, presented as the percentage of patients in each weight/BMI category, overall and by country. Percentages are slightly under or over 100% due to rounding.

(a)



(b)




Supplementary Fig. 5


Treatments by line of therapy and disease severity at

treatment initiation for patients with a complete treatment history for the overall patient population in each country. Percentages for each regimen line add up to >100% as patients could receive multiple treatments for each regimen line.


(a) France




(b) Germany



(c) Italy



(d) Spain



(e) UK

